BRAF and neoplasm: While RAS itself is considered as “undruggable”, inhibitors of both mutant BRAF and wild type MEK have been approved as first line treatments for locally-advanced and metastatic melanoma and have demonstrated improved tumor response rate and progression free survival (PFS) [8,9].